- Conditions
- Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV
- Interventions
- Bemnifosbuvir, Ruzasvir
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteer Study
- Interventions
- Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy Volunteer Study
- Interventions
- Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION
- Interventions
- Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 84 more
- Conditions
- Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
- Interventions
- Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Tampa, Florida
- Conditions
- Healthy Volunteer Study
- Interventions
- Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey